Alfons JM van den Eertwegh

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Alfons JM van den Eertwegh, Jurjen Versluis, H. Pieter van den Berg et al. · The Lancet Oncology · 2012 · 357 citations

Medicine, Immunology, Oncology +16

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Saskia J. Santegoets, Anita G.M. Stam, Sinéad M. Lougheed et al. · Journal for ImmunoTherapy of Cancer · 2014 · 106 citations · Full text

Medicine, Immunology, Oncology +17

IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells

Saskia J. Santegoets, Annelies W. Turksma, Megan M. Suhoski et al. · Journal of Translational Medicine · 2013 · 94 citations · Full text

Life Sciences, Immunology, Oncology +17

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Dennis A. Revicki, Alfons JM van den Eertwegh, Paul Lorigan et al. · Health and Quality of Life Outcomes · 2012 · 62 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Natural Killer T cells

Herbert M. Pinedo, B. Mary E. von Blomberg, Alfons JM van den Eertwegh et al. · The Lancet Oncology · 2002 · 21 citations

Life Sciences, Immunology, Cellular Immunology +10